Biological Samples and Additional Research Sample Clauses

Biological Samples and Additional Research. Institution and Principal Investigator shall not, without the prior written consent of Janssen, conduct any 1.10 Biologické vzorky a další výzkum: Zdravotnické zařízení a hlavní zkoušející nesmí, bez předchozího písemného souhlasu společnosti Janssen, provádět research or facilitate third parties to žádný výzkum, který není vyžadován conduct any research that is not not protokolem (ani nesmí třetím stranám required by the Protocol on (i) Trial Subjects umožnit žádný takový výzkum provádět): (i) during the Clinical Trial (including any na subjektech hodnocení během klinického additional research technique, procedure, hodnocení (to se týká jakýchkoli questionnaire, or observation), or (ii) výzkumných technik, postupů, dotazníků či biological samples collected from Trial pozorování); ani (ii) s využitím bilogických Subjects during the Clinical Trial, or (iii) the vzorků odebraných od subjektů hodnocení data derived from the Clinical Trial. během klinického hodnocení; ani (iii) Hereinafter, the research described in the používat k výzkumu údaje odvozené z previous sentence shall be referred to as klinického hodnocení. Výzkum popsaný v “Additional Research”. In any case where předchozí větě bude v této smlouvě dále Janssen gives such approval, the approved označován jako "další výzkum". V případě, Additional Research shall be considered že společnost Janssen schválí další výzkum, either an amendment to the original bude tento schválený další výzkum Protocol, or shall be the subject of another považován buď za dodatek k původnímu written agreement between Institution, protokolu nebo bude předmětem CRO and Janssen. Institution and Principal samostatné písemné smlouvy uzavřené Investigator shall conduct all Additional mezi zdravotnickým zařízením, hlavním Research in compliance with all applicable zkoušejícím, CRO a společností Janssen. regulations, including requirements for Zdravotnické zařízení se zavazuje provádět obtaining appropriate EC approval and veškerý další výzkum v souladu s subject informed consent. Without limiting ustanovením všech platných zákonů, a to any other remedy available by law to včetně požadavků týkajících se získání Janssen, if Institution conducts Additional příslušného souhlasu ze strany etické Research in breach of this section, and such komise a získání informovaného souhlasu Additional Research results in an Invention od subjektů hodnocení. Aniž by tím byla (as defined in Section 8 below), Institution dotčeny ostatní opravné prostř...
AutoNDA by SimpleDocs

Related to Biological Samples and Additional Research

  • Selection of Subcontractors, Procurement of Materials and Leasing of Equipment The contractor shall not discriminate on the grounds of race, color, religion, sex, national origin, age or disability in the selection and retention of subcontractors, including procurement of materials and leases of equipment. The contractor shall take all necessary and reasonable steps to ensure nondiscrimination in the administration of this contract. a. The contractor shall notify all potential subcontractors and suppliers and lessors of their EEO obligations under this contract. b. The contractor will use good faith efforts to ensure subcontractor compliance with their EEO obligations.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Research Use Reporting To assure adherence to NIH GDS Policy, the PI agrees to provide annual Progress Updates as part of the annual Project Renewal or Project Close-out processes, prior to the expiration of the one (1) year data access period. The PI who is seeking Renewal or Close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the PI is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The PI also may include general comments regarding suggestions for improving the data access process in general. Information provided in the progress updates helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH’s effort to provide ongoing stewardship of data sharing activities subject to the NIH GDS Policy.

  • Infectious Diseases The Employer and the Union desire to arrest the spread of infectious diseases in the nursing home. To achieve this objective, the Joint Health and Safety Committee may review and offer input into infection control programs and protocols including surveillance, outbreak control, isolation, precautions, worker education and training, and personal protective equipment. The Employer will provide training and ongoing education in communicable disease recognition, use of personal protective equipment, decontamination of equipment, and disposal of hazardous waste.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Supply of Materials The following materials will be supplied by the department Name of Materials Rate. Place of delivery 1.

  • Substance Abuse Treatment Information Substance abuse treatment information shall be maintained in compliance with 42 C.F.R. Part 2 if the Party or subcontractor(s) are Part 2 covered programs, or if substance abuse treatment information is received from a Part 2 covered program by the Party or subcontractor(s).

  • Solicitations for Subcontracts, Including Procurement of Materials and Equipment In all solicitations either by competitive bidding or negotiation made by the Local Government for work to be performed under a subcontract, including procurement of materials or leases of equipment, each potential subcontractor or supplier will be notified by the Local Government of the Local Government’s obligations under this Agreement and the Acts and Regulations relative to Nondiscrimination on the grounds of race, color, or national origin.

  • Quality of Materials and workmanship The Contractor shall ensure that the Construction, Materials and workmanship are in accordance with the requirements specified in this Agreement, Specifications and Standards and Good Industry Practice.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!